Form 8-K - Current report:
SEC Accession No. 0001558370-23-011180
Filing Date
2023-06-16
Accepted
2023-06-16 16:15:29
Documents
14
Period of Report
2023-06-13
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.03: Material Modifications to Rights of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K fbio-20230613x8k.htm   iXBRL 8-K 40236
2 EX-4.1 fbio-20230613xex4d1.htm EX-4.1 98111
  Complete submission text file 0001558370-23-011180.txt   316701

Data Files

Seq Description Document Type Size
3 EX-101.SCH fbio-20230613.xsd EX-101.SCH 4440
4 EX-101.DEF fbio-20230613_def.xml EX-101.DEF 14629
5 EX-101.LAB fbio-20230613_lab.xml EX-101.LAB 16576
6 EX-101.PRE fbio-20230613_pre.xml EX-101.PRE 14301
8 EXTRACTED XBRL INSTANCE DOCUMENT fbio-20230613x8k_htm.xml XML 7224
Mailing Address 1111 KANE CONCOURSE SUITE 301 BAY HARBOR ISLANDS FL 33154
Business Address 1111 KANE CONCOURSE SUITE 301 BAY HARBOR ISLANDS FL 33154 781-652-4500
Fortress Biotech, Inc. (Filer) CIK: 0001429260 (see all company filings)

EIN.: 205157386 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35366 | Film No.: 231021298
SIC: 2834 Pharmaceutical Preparations